Disrupted neurotrophin signaling contributes to and coincides with the progression of NFT pathology in AD patients (Tiernan et al. 2018), and in turn, phosphorylated tau (pS422+ neurons) may impair NGF retrograde transport (Tiernan et al. 2016) and inhibit TrkA expression and therefore support the shift from pro‐survival to proapoptotic signaling (Tiernan et al. 2018). Here, MAPT is linked to Alzheimer disease.